AstraZeneca is about to find out whether its third-to-market respiratory biologic can stand out from a crowd that includes rivals GSK and Teva.
Back in August, Novartis published findings from the phase 3 Cantos trial of Ilaris that weren't "fully compelling to payers."
The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.
With time running short, EU members have been asked to set aside parochial interests in their pick for a new city to host the EMA.
President Donald Trump tweeted his nomination for ex-Eli Lilly executive Alex Azar as HHS secretary Monday morning.
FDA Commissioner Scott Gottlieb has unveiled yet another move to step up competition in the generics business.
Merck’s drug for chemo-induced nausea and vomiting has some new competition.
Those waiting for Hikma and Vectura’s copy of GlaxoSmithKline blockbuster Advair may be waiting awhile.
Merck's antiviral business suffered some serious blows this year, but it now boasts a new product: Prevymis, a CMV fighter approved by the FDA on Thursday.
Despite blasting pharma for "getting away with murder," President Donald Trump is close to naming a former Eli Lilly executive as HHS secretary.